Literature DB >> 1384425

Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma.

G J Hart1, D C Orr, C R Penn, H T Figueiredo, N M Gray, R E Boehme, J M Cameron.   

Abstract

(-)-2'-Deoxy-3'-thiacytidine (3TC) is a selective inhibitor of human immunodeficiency virus replication in vitro (J. A. V. Coates, N. Cammack, H. J. Jenkinson, A. J. Jowett, M. I. Jowett, B. A. Pearson, C. R. Penn, P. L. Rouse, K. C. Viner, and J. M. Cameron, Antimicrob. Agents Chemother. 36:733-739, 1992). The effect of 3TC 5'-triphosphate on both the RNA-dependent and DNA-dependent activities of human immunodeficiency virus type 1 reverse transcriptase and DNA polymerases alpha, beta, and gamma from HeLa cells was investigated. 3TC 5'-triphosphate is a competitive inhibitor (with respect to dCTP) of the RNA-dependent DNA polymerase activity (apparent Ki = 10.6 +/- 1.0 to 1.24 +/- 5.1 microM, depending on the template and primer used); the DNA-dependent DNA polymerase activity is 50% inhibited by a 3TC 5'-triphosphate concentration of 23.4 +/- 2.5 microM when dCTP is present at a concentration equal to its Km value. Chain elongation studies show that 3TC 5'-triphosphate is incorporated into newly synthesized DNA and that transcription is terminated in a manner identical to that found for ddCTP. The 50% inhibitory concentrations of 3TC 5'-triphosphate against DNA polymerases alpha, beta, and gamma at concentrations of dCTP equal to the Km were 175 +/- 31, 24.8 +/- 10.9, and 43.8 +/- 16.4 microM, respectively. More detailed kinetic studies with 3TC 5'-triphosphate and DNA polymerases beta and gamma are consistent with the fact that inhibition of these enzymes by 3TC 5'-triphosphate is competitive with respect to dCTP. The values of Ki were determined to be 18.7 microM for DNA polymerase beta and 15.8 +/- 0.8 microM for DNA polymerase gamma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1384425      PMCID: PMC192031          DOI: 10.1128/AAC.36.8.1688

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Enzymatic synthesis of deoxyribonucleic acid. IX. The polymerase formed after T2 bacteriophage infection of Escherichia coli: a new enzyme.

Authors:  H V APOSHIAN; A KORNBERG
Journal:  J Biol Chem       Date:  1962-02       Impact factor: 5.157

2.  HeLa cell DNA polymerase gamma: further purification and properties of the enzyme.

Authors:  K W Knopf; M Yamada; A Weissbach
Journal:  Biochemistry       Date:  1976-10-05       Impact factor: 3.162

3.  Comparison of the effect of Carbovir, AZT, and dideoxynucleoside triphosphates on the activity of human immunodeficiency virus reverse transcriptase and selected human polymerases.

Authors:  E L White; W B Parker; L J Macy; S C Shaddix; G McCaleb; J A Secrist; R Vince; W M Shannon
Journal:  Biochem Biophys Res Commun       Date:  1989-06-15       Impact factor: 3.575

4.  Metabolic pathways for the activation of the antiretroviral agent 2',3'-dideoxyadenosine in human lymphoid cells.

Authors:  M A Johnson; G Ahluwalia; M C Connelly; D A Cooney; S Broder; D G Johns; A Fridland
Journal:  J Biol Chem       Date:  1988-10-25       Impact factor: 5.157

5.  Herpes simplex virus type 1 and human DNA polymerase interactions with 2'-deoxyguanosine 5'-triphosphate analogues. Kinetics of incorporation into DNA and induction of inhibition.

Authors:  J E Reardon
Journal:  J Biol Chem       Date:  1989-11-15       Impact factor: 5.157

6.  Preparation and preliminary characterization of monoclonal antibodies against human DNA polymerase alpha.

Authors:  S Tanaka; S Z Hu; T S Wang; D Korn
Journal:  J Biol Chem       Date:  1982-07-25       Impact factor: 5.157

7.  Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity.

Authors:  C H Chen; M Vazquez-Padua; Y C Cheng
Journal:  Mol Pharmacol       Date:  1991-05       Impact factor: 4.436

8.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

9.  Cellular metabolism of (-) enantiomeric 2'-deoxy-3'-thiacytidine.

Authors:  N Cammack; P Rouse; C L Marr; P J Reid; R E Boehme; J A Coates; C R Penn; J M Cameron
Journal:  Biochem Pharmacol       Date:  1992-05-28       Impact factor: 5.858

10.  Cellular metabolism of 2',3'-dideoxycytidine, a compound active against human immunodeficiency virus in vitro.

Authors:  M C Starnes; Y C Cheng
Journal:  J Biol Chem       Date:  1987-01-25       Impact factor: 5.157

View more
  44 in total

1.  Presteady state kinetic investigation of the incorporation of anti-hepatitis B nucleotide analogues catalyzed by noncanonical human DNA polymerases.

Authors:  Jessica A Brown; Lindsey R Pack; Jason D Fowler; Zucai Suo
Journal:  Chem Res Toxicol       Date:  2011-12-16       Impact factor: 3.739

2.  Model for intracellular Lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents.

Authors:  Zexun Zhou; John H Rodman; Patricia M Flynn; Brian L Robbins; Carrie K Wilcox; David Z D'Argenio
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

Review 3.  Mechanistic cross-talk between DNA/RNA polymerase enzyme kinetics and nucleotide substrate availability in cells: Implications for polymerase inhibitor discovery.

Authors:  Si'Ana A Coggins; Bijan Mahboubi; Raymond F Schinazi; Baek Kim
Journal:  J Biol Chem       Date:  2020-07-31       Impact factor: 5.157

4.  Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.

Authors:  R F Schinazi; R M Lloyd; M H Nguyen; D L Cannon; A McMillan; N Ilksoy; C K Chu; D C Liotta; H Z Bazmi; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

Review 5.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

6.  Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.

Authors:  M Tisdale; S D Kemp; N R Parry; B A Larder
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

Review 7.  Clinical pharmacokinetics of lamivudine.

Authors:  M A Johnson; K H Moore; G J Yuen; A Bye; G E Pakes
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

8.  Exonuclease removal of dideoxycytidine (zalcitabine) by the human mitochondrial DNA polymerase.

Authors:  Jeremiah W Hanes; Kenneth A Johnson
Journal:  Antimicrob Agents Chemother       Date:  2007-11-05       Impact factor: 5.191

Review 9.  The mitochondrial DNA polymerase in health and disease.

Authors:  William C Copeland
Journal:  Subcell Biochem       Date:  2010

10.  Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(--)-beta-L-2', 3'-dideoxy-3'-thiacytidine] in vitro.

Authors:  K P Fischer; D L Tyrrell
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.